{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:02:41Z","timestamp":1775833361797,"version":"3.50.1"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,24]]},"DOI":"10.7759\/cureus.97631","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T10:58:01Z","timestamp":1763981881000},"source":"Crossref","is-referenced-by-count":2,"title":["Immune Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus: An Indian Case Series"],"prefix":"10.7759","author":[{"given":"Medha N","family":"Rao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditi","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya G","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adarsh K","family":"S","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunna","family":"Sriharsha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad670","article-title":"Risk and incidence of endocrine immune-related adverse effects under checkpoint inhibitor mono- or combination therapy in solid tumors: a meta-analysis of randomized controlled trials","volume":"109","author":"Vardarli I","year":"2024","unstructured":"Vardarli I, Tan S, Brandenburg T, Weidemann F, G\u00f6rges R, Herrmann K, F\u00fchrer D. Risk and incidence of endocrine immune-related adverse effects under checkpoint inhibitor mono- or combination therapy in solid tumors: a meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2024, 109:1132-44. 10.1210\/clinem\/dgad670","journal-title":"J Clin Endocrinol Metab"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13424","article-title":"Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes","volume":"200","author":"Quandt Z","year":"2020","unstructured":"Quandt Z, Young A, Anderson M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin Exp Immunol. 2020, 200:131-40. 10.1111\/cei.13424","journal-title":"Clin Exp Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-2202","article-title":"Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM): a systematic review and delineation from type 1 diabetes","volume":"46","author":"Wu L","year":"2023","unstructured":"Wu L, Tsang V, Menzies AM, et al.. Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM): a systematic review and delineation from type 1 diabetes. Diabetes Care. 2023, 46:1292-9. 10.2337\/dc22-2202","journal-title":"Diabetes Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-024-01077-6","article-title":"Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors","volume":"21","author":"Iwama S","year":"2025","unstructured":"Iwama S, Kobayashi T, Arima H. Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors. Nat Rev Endocrinol. 2025, 21:289-300. 10.1038\/s41574-024-01077-6","journal-title":"Nat Rev Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2023.0072","article-title":"Immune-checkpoint inhibitors-induced type 1 diabetes mellitus: from its molecular mechanisms to clinical practice","volume":"47","author":"Cho YK","year":"2023","unstructured":"Cho YK, Jung CH. Immune-checkpoint inhibitors-induced type 1 diabetes mellitus: from its molecular mechanisms to clinical practice. Diabetes Metab J. 2023, 47:757-66. 10.4093\/dmj.2023.0072","journal-title":"Diabetes Metab J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-024-01263-6","article-title":"Distinct changes to pancreatic volume rather than pancreatic autoantibody positivity: insights into immune checkpoint inhibitors induced diabetes mellitus","volume":"16","author":"Wei HH","year":"2024","unstructured":"Wei HH, Lai YC, Lin G, et al.. Distinct changes to pancreatic volume rather than pancreatic autoantibody positivity: insights into immune checkpoint inhibitors induced diabetes mellitus. Diabetol Metab Syndr. 2024, 16:26. 10.1186\/s13098-024-01263-6","journal-title":"Diabetol Metab Syndr"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1589630","article-title":"Immune checkpoint inhibitor-associated diabetes mellitus: the case series report","volume":"16","author":"Ma Y","year":"2025","unstructured":"Ma Y, Xue J, Cheng Q, Qian H, Du Y. Immune checkpoint inhibitor-associated diabetes mellitus: the case series report. Front Endocrinol (Lausanne). 2025, 16:1589630. 10.3389\/fendo.2025.1589630","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye ES","year":"2022","unstructured":"Husebye ES, Castinetti F, Criseno S, et al.. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022, 187:G1-21. 10.1530\/EJE-22-0689","journal-title":"Eur J Endocrinol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/433092-immune-checkpoint-inhibitor-associated-autoimmune-diabetes-mellitus-an-indian-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T10:58:01Z","timestamp":1763981881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/433092-immune-checkpoint-inhibitor-associated-autoimmune-diabetes-mellitus-an-indian-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.97631","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,24]]}}}